Intra-Cellular Therapies Stock Forecast, Price & News

Intra-Cellular Therapies' stock was trading at $17.77 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, ITCI shares have increased by 46.9% and is now trading at $26.10.
View which stocks have been most impacted by COVID-19.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Intra-Cellular Therapies in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Intra-Cellular Therapies.

Intra-Cellular Therapies is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020.
View our earnings forecast for Intra-Cellular Therapies.

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) announced its quarterly earnings data on Monday, August, 10th. The biopharmaceutical company reported ($0.96) earnings per share for the quarter, missing the consensus estimate of ($0.94) by $0.02. The biopharmaceutical company earned $1.91 million during the quarter, compared to the consensus estimate of $3.05 million.
View Intra-Cellular Therapies' earnings history.

6 Wall Street analysts have issued twelve-month target prices for Intra-Cellular Therapies' shares. Their forecasts range from $26.00 to $80.00. On average, they anticipate Intra-Cellular Therapies' stock price to reach $53.33 in the next twelve months. This suggests a possible upside of 104.3% from the stock's current price.
View analysts' price targets for Intra-Cellular Therapies.

Intra-Cellular Therapies saw a drop in short interest in September. As of September 30th, there was short interest totaling 5,870,000 shares, a drop of 12.9% from the September 15th total of 6,740,000 shares. Based on an average daily trading volume, of 1,820,000 shares, the days-to-cover ratio is currently 3.2 days.
View Intra-Cellular Therapies' Short Interest.

Some companies that are related to Intra-Cellular Therapies include ACADIA Pharmaceuticals (ACAD), Ionis Pharmaceuticals (IONS), Bausch Health Companies (BHC), Perrigo (PRGO), Arrowhead Pharmaceuticals (ARWR), Blueprint Medicines (BPMC), Ultragenyx Pharmaceutical (RARE), United Therapeutics (UTHR), Emergent Biosolutions (EBS), BridgeBio Pharma (BBIO), Amicus Therapeutics (FOLD), Biohaven Pharmaceutical (BHVN), Arena Pharmaceuticals (ARNA), Allakos (ALLK) and Turning Point Therapeutics (TPTX).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Intra-Cellular Therapies investors own include Sorrento Therapeutics (SRNE), Amarin (AMRN), Gilead Sciences (GILD), Crispr Therapeutics (CRSP), Synergy Pharmaceuticals (SGYP), Myovant Sciences (MYOV), Novavax (NVAX), Pfizer (PFE), AbbVie (ABBV) and Clovis Oncology (CLVS).

Intra-Cellular Therapies trades on the NASDAQ under the ticker symbol "ITCI."

Intra-Cellular Therapies' stock is owned by a variety of institutional and retail investors. Top institutional investors include Assenagon Asset Management S.A. (0.71%), Candriam Luxembourg S.C.A. (0.64%), Pinnacle Associates Ltd. (0.39%), First Midwest Bank Trust Division (0.34%), Franklin Street Advisors Inc. NC (0.08%) and Gemmer Asset Management LLC (0.02%). Company insiders that own Intra-Cellular Therapies stock include Andrew Satlin, Christopher D Alafi, Joel S Marcus, Kimberly E Vanover, Lawrence J Hineline, Mark Neumann, Michael Halstead, Robert E Davis and Sharon Mates.
View institutional ownership trends for Intra-Cellular Therapies.

ITCI stock was sold by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A., First Midwest Bank Trust Division, Pinnacle Associates Ltd., Nisa Investment Advisors LLC, and Gemmer Asset Management LLC. Company insiders that have sold Intra-Cellular Therapies company stock in the last year include Andrew Satlin, Joel S Marcus, Lawrence J Hineline, Mark Neumann, Michael Halstead, and Sharon Mates.
View insider buying and selling activity for Intra-Cellular Therapies.

ITCI stock was acquired by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Campbell & CO Investment Adviser LLC, and Franklin Street Advisors Inc. NC.
View insider buying and selling activity for Intra-Cellular Therapies.

Shares of ITCI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ITCI stock can currently be purchased for approximately $26.10.

Intra-Cellular Therapies has a market capitalization of $1.76 billion and generates $60,000.00 in revenue each year. The biopharmaceutical company earns $-147,720,000.00 in net income (profit) each year or ($2.68) on an earnings per share basis. Intra-Cellular Therapies employs 330 workers across the globe.

The official website for Intra-Cellular Therapies is www.intracellulartherapies.com.

Intra-Cellular Therapies' mailing address is 430 EAST 29TH STREET, NEW YORK NY, 10016. The biopharmaceutical company can be reached via phone at 646-440-9333 or via email at [email protected]